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Abstract Available evidence supports the efficacy of pre-
exposure prophylaxis (PrEP) in decreasing the incidence of
human immunodeficiency virus (HIV) infection among
high-risk individuals, especially when used in combination
with other behavioural preventive methods. Safety concerns
about PrEP present challenges in the implementation and use
of PrEP. The aim of this review is to discuss safety concerns
observed in completed clinical trials on the use of PrEP. We
performed a literature search on PrEP in PubMed, global
advocacy for HIV prevention (Aids Vaccine Advocacy
Coalition) database, clinical trials registry ‘‘http://www.
clinicaltrials.gov’’ and scholar.google, using combination
search terms ‘pre-exposure prophylaxis’, ‘safety concerns in
the use of pre-exposure prophylaxis’, ‘truvada use as PrEP’,
‘guidelines for PrEP use’, ‘HIV pre-exposure prophylaxis’
and ‘tenofovir’ to identify clinical trials and literature on
PrEP. We present findings associated with safety issues on
the use of PrEP based on a review of 11 clinical trials on PrEP
with results on safety and efficacy as at April 2016. We also
reviewed findings from routine real-life practice reports. The
pharmacological intervention for PrEP was tenofovir diso-
proxil fumarate/emtricitabine in a combined form as Tru-
vada or tenofovir as a single entity. Both products are
efficacious for PrEP and seem to have a good safety profile.
Regular monitoring is recommended to prevent long-term
toxic effects. The main adverse effects observed with PrEP
are gastrointestinal related; basically mild to moderate nau-
sea, vomiting and diarrhea. Other adverse drug effects worth
monitoring are liver enzymes, renal function and bone
mineral density. PrEP as an intervention to reduce HIV
transmission appears to have a safe benefit-risk profile in
clinical trials. It is recommended for widespread use but
adherence monitoring and real-world safety surveillance are
critical in the post-marketing phase to ensure that the benefits
observed in clinical trials are maintained in real-world use.
Key Points
Safety concerns about pre-exposure prophylaxis pose
challenges in use that should not be overlooked.
Behavioural counselling and assurance of safety and
efficacy are important components of pre-exposure
prophylaxis.
Real-world safety surveillance is critical in the post-
marketing phase to ensure that the benefits observed
in clinical trials are maintained.
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1 Introduction
At the end of 2015, the World Health Organization
established that 36.7 million people were living with
human immunodeficiency virus (HIV) with about 2.1
million becoming newly infected in the year [1]. With this
high prevalence of HIV/acquired immune deficiency syn-
drome in the world, the World Health Organization related
the urgency and importance of novel, effective and safe
interventions in the prevention of HIV infection. This
became necessary in that preventive behavioural messages
on abstinence, faithfulness and condom use presented
useful but limited impact as primary prevention on the
spread of HIV. This challenge is observed especially
among people at high risk because these protective mea-
sures were not applied consistently [2].
Human immunodeficiency virus continues to be a major
public health problem and it has claimed more than 35
million lives so far. In 2015 alone, 1.1 million died from
HIV-related causes worldwide [1]. The various manage-
ment options for HIV including treatment, post-exposure
prophylaxis and prevention of mother-to-child transmission
have been integral in lowering HIV incidence, but reaching
out to individuals at substantial risk owing to lifestyle
practices required newer specific preventive approaches.
Pre-exposure prophylaxis (PrEP) is a powerful tool in
curbing the transmission of HIV infection [3], and it
involves taking an antiretroviral (ARV) pill daily in addi-
tion to other preventive behavioural measures to prevent
HIV infection. This is a protective mechanism used for
individuals not diagnosed with HIV but who may be at
substantial risk of becoming infected because of their
lifestyle or as a partner in a sero-discordant relationship.
Results from clinical trials demonstrate the efficacy of
PrEP, either used alone or in combination with other
behavioural preventive methods, where it has been shown
that PrEP can reduce the incidence of HIV by up to 86%
[4, 5] or even more with strict adherence. Based on results
and evidence from PrEP trials, the US Food and Drug
Administration (FDA) on 16 July, 2012 approved Tru-
vada [tenofovir (TDF) 300 mg/emtricitabine (FTC)
200 mg] (Gilead Sciences Inc., Foster City, CA, USA) as
an effective medication for the prevention of HIV that
could be sexually acquired [6, 7] and in all other types of
possible HIV infection including injectable drug use. This
was followed with guidelines for the provision of PrEP in
clinical settings issued by the US Centers for Disease
Control (CDC) and recently the World Health Organization
also issued similar guidelines recommending PrEP as a
prevention option for individuals at substantial risk for
acquiring HIV [8, 9].
In the 2014 CDC guidelines, TDF alone based on
positive results of substantial efficacy and safety in clin-
ical trials with injectable drug use and heterosexual active
adults was recommended as an alternative regimen for
these populations, but not for men who have sex with
men (MSM) because no efficacy studies were concluded
as yet in the group. Again, the use of other antiretroviral
medications for PrEP, either in place of or in addition to
TDF/FTC or TDF alone is not recommended and finally
the use of oral PrEP for sex activity-timed or noncon-
tinuous daily use is also not recommended [8]. The CDC
also recommend in addition to regular follow-up testing
for changes in HIV-negative status and adverse drug
monitoring including renal function before the initiation
of PrEP and regularly while on preventive therapy.
Routine bone mineral density (BMD) monitoring was not
recommended by the CDC [8].
There are several challenges in the implementation and
use of PrEP. These concerns include high costs, safety
screening, toxicity arising from continuous use, adverse
drug reactions, poor adherence, possible abuse and the fear
of decreased condom use as an additional protective
method [10, 11]. Poor adherence during PrEP is especially
an important factor that may reduce effectiveness and lead
to an increase in HIV infection rate with a possible
development of HIV-resistant strains and subsequent
transfer among the population. Factors that can affect
adherence include adverse drug reactions (at regular doses)
or toxicity (adverse drug reactions at probable high,
intolerant doses or long-term use).
The ARV drugs presently recommended for oral PrEP
are TDF or a combination of TDF/FTC. These medica-
tions have proven to be potent [12–14], have a favourable
resistance profile and are claimed to have limited adverse
effects, thus rendering them efficacious and safe for PrEP
[14–17]. Some studies have also assessed the efficacy of a
1% vaginal gel formulation of TDF and found it to be
effective in reducing HIV transmission by 39% [18].
Essential factors to be considered before using PrEP
include a confirmed HIV-negative status with a normal
renal function, a negative hepatitis B status, and absence
of reduced BMD or a history of bone fractures, bone loss
and osteoporosis [19, 20]. Recipients of PrEP also need to
be tested on a minimum of a quarterly basis during fol-
low-up to ensure they remain HIV negative, do not pre-
sent with decreased estimated creatinine clearance levels
or reductions in BMD [21]. The aim of this review is to
describe and discuss safety concerns on the use of PrEP
in the literature. Results from this review will contribute
to the growing knowledge on the safety profile or use of
PrEP.
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2 Methods
We performed a search of the literature on PrEP in PubMed
(search date: 10 May, 2016), scholar.google (search date:
11 May, 2016), global advocacy for HIV prevention (Aids
Vaccine Advocacy Coalition) database (search date: 12
May, 2016) and the clinical trials, ‘‘http://www.
clinicaltrials.gov’’ (search date: 13 May, 2016), using
combination search terms ‘pre-exposure prophylaxis’,
‘safety concerns in the use of pre-exposure prophylaxis’,
‘truvada use as PrEP’, ‘guidelines for PrEP use’, ‘HIV pre-
exposure prophylaxis’ and ‘tenofovir’ to identify literature
on PrEP safety trials and issues. The coverage dates were
from January 2001 to April 2016. We limited the search to
articles in English, which were completed with results
available and based on the safety or efficacy of TDF, FTC
and TDF/FTC. We profiled our findings on safety concerns
of PrEP. Information on clinical trials was extracted from
PubMed, Aids Vaccine Advocacy Coalition and clinical-
trials.gov based on completed studies (Fig. 1).
In the clinical trials database, studies that were enrolling
or incomplete at the time of this review were excluded.
Seventy-two cases were retrieved. We modified the search
for closed and completed studies and reduced the number
to 42. Further modification with emphasis on the drugs of
interest reduced the trials to 23. We then isolated nine
studies that were complete with results and enough data for
our review (Fig. 1).
In PubMed, we obtained 938 articles after the initial
search. We then limited the search to only clinical trials
and obtained 79. We then modified to include only trials
involving TDF/FTC and TDF and got 35 articles. From
here, we isolated 29 articles that were completed and had
results. We then focused on efficacy and safety, and
retrieved nine articles.
For AVAC, the initial search on PrEP and then clinical
trials and product development yielded 38 articles; we then
selected completed studies and obtained 14 articles. We
then modified to focus on efficacy and safety and isolated
eight articles. We then isolated 11 studies that appeared in
all three search engines that satisfied our review require-
ments and used these for our review and discussion
(Fig. 1).
3 Results
3.1 Clinical Trials Supporting the Use of PrEP
Numerous trials involving both humans and animals have
tested oral and vaginal routes of administration of PrEP and
have been found efficacious in preventing HIV. The basis
for PrEP stems from results of clinical and epidemiological
research [22–25]. We reviewed 11 clinical trials on PrEP
among different risk groups conducted from 2005 to 2015.
These trials had results at the time of our study and allowed
for review. Results from literature on PrEP studies are not
necessarily universal. The efficacy ranges from lack of
protection to protection levels of as high as 96%, attesting
to the complex nature of PrEP implementation [26]. Aside
from the effectiveness of PrEP in most of the studies cited,
the Vaginal and Oral Interventions to Control the Epidemic
(VOICE) [27] and Preexposure Prophylaxis Trial for HIV
Prevention among African Women (FEM-PrEP) [28]
studies were terminated ahead of time because the analysis
failed to demonstrate efficacy attributed to poor adherence.
Results for the VOICE study differ with findings in three
other placebo-controlled vaginal PrEP trials [Partners PrEP
[14], TDF2 [17], Iniciativa Profilaxis Pre-Exposicion
(iPrEx) and [16] one placebo-controlled vaginal gel trial
[Centre for AIDS program of Research in South Africa
(CAPRISA 004)] [18]. Partners PrEP [14] studied Tru-
vada and TDF alone in HIV-discordant committed Afri-
can couples, TDF2 [17] studied heterosexual African
women and men, iPrEx [16] studied gay and bisexual men
on four continents and CAPRISA 004 [18] studied South
African women. Poor adherence as in FEM-PrEP was the
main reason for failure in all three VOICE arms. Among
334 women who became infected with HIV, 22 entered the
trial with acute HIV infection. With their exclusion, HIV
incidence was 5.7 per 100 person-years, meaning about 6
in every 100 women got infected in every 12 months. HIV
incidence rates per 100 person-years were 6.3 and 4.2 for
oral TDF vs. placebo, 4.7 and 4.6 for Truvada vs. placebo,
and 5.9 and 6.8 for TDF gel vs. placebo; therefore, none of
the three strategies worked as hazard ratios (HRs) was for
oral TDF: HR 1.49 [95% confidence interval (CI)
0.97–2.29], oral Truvada: HR 1.04 (95% CI 0.73–1.49)
and TDF gel: HR 0.85 (95% CI 0.6–1.2). In all cases,
women reported 90–91% adherence with return data sug-
gesting the same, but TDF concentrations in plasma told
another story: 30% or fewer women in all three treatment
arms had detectable concentrations in plasma: 30% in oral
TDF, 29% in oral Truvada and 25% using TDF gel. In all
three again, 50% or more women never had
detectable blood in any sample. Three factors predicted
detectable TDF in plasma: first, being married (adjusted
odds ratio = 2.24 [95% CI, 1.12–4.49]), the second being
older than 25 years (adjusted odds ratio = 1.62 [95% CI,
1.12–2.34]), and the third being multiparous (adjusted odds
ratio = 1.84 [95% CI, 1.26–2.69]).
The FEM-PrEP [28] study of 2120 participants reported
56 new HIV infections 14 months after initiation of the
study with the infections equally distributed between Tru-
vada and placebo groups (28 in each arm), clearly indi-
cating the lack of protection in the use of Truvada.
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Overall adherence (based on participants self-report) was
95% with no clear difference in adherence between the two
arms.
These two results revealed that ‘‘products that are long
acting and require minimum daily adherence may be
more suitable for the population under study’’ contrary to
positive results posted by the other findings, which sug-
gest that young, sexually active, single people can be
motivated to take oral Truvada or TDF gel regularly
enough to protect themselves from HIV. However, the
CAPRISA 004 trial [18] differed from the FEM-PrEP [28]
and VOICE [27] studies by determining a 65% protection
against HIV at a TDF concentration of[100 ng/mL and
up to 76% with a TDF concentration of[1000 ng/mL.
Results from Pre-exposure Prophylaxis to Prevent the
Acquisition of HIV-1 Infection (PROUD) [29] in the UK
and Intervention Preventive de l’Exposition aux Risques
avec Risques avec et pour les Gays (Ipergay) [5] in
France both showed that PrEP reduced infections among
gay men by 86%. None of the participants on PrEP
involved in these studies acquired HIV. PrEP was also
found to be effective for heterosexual men and women: a
study in East Africa (Partners) [14] reduced possible HIV
infection within couples in which one partner was positive
by 75%. The iPrEx study also found that the HIV
infection rate in HIV-negative gay men who were given a
daily pill containing Truvada was reduced by 44%,
compared with men given placebo. Those who confirmed
adherence at 90% had a reduction rate of up to 73%. The
TDF2 trial in Botswana gave a reduction rate of 63%
against placebo and 77.9% after secondary analysis;
therefore, confirming the obvious benefit in the use of
PrEP. The Bangkok Tenofovir Study [30] focused on men
and women who inject drugs and found that the risk of
acquiring HIV reduced by 49% and up to 79% in those
who adhered consistently to their medication. The study
also found that participants taking TDF were more likely
to experience nausea and or/vomiting than those in the
placebo group. No indication of elevated creatinine or
renal impairment in the TDF group was reported.
Articles included  
n=26, 2.5% of total citations 
Exclusions based on data duplication (n=15) 
PubMed citations 
(n=938, 89.5 % of citations)
Clinicaltrials.gov 
(n=72, 6.9% of citations) 
AVAC 
(n=38, 3.6% of citations) 
Total citations 
(n=1048) 
Exclusions based on abstract  
• Study not clinical trial (n=859) 
Full text articles reviewed 
n=189, 18.0 % of total citations 
Exclusions based on full text review 
• Study did not report on TDF/FTC or TDF (n=30) 
• Study not completed (n=44) 
Potentially appropriate articles 
n=115, 11.0% of total citations 
Exclusions based on data review 
  Study did not present data on safety (n=89) 
Unique articles included in review 
(n=11, 1.0 % of total citations, 5.8% of full text reviewed) 
Fig. 1 Chart of search strategy for clinical trials on pre-exposure prophylaxis based on tenofovir (TDF), emtricitabine (FTC) and a TDF/FTC
combination. AVAC Aids Vaccine Advocacy Coalition
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The PrEP study in USA with 373 participants with 186
taking TDF and 187 taking placebo was successful with
[31] only four on placebo and three among the delayed-arm
participants seroconverting. Estimated adherence by pill
load was 92% and by medication event monitoring system
was 77%. Oral TDF was well tolerated with no significant
renal concerns, while adverse drug events reported did not
differ significantly between TDF and placebo arms.
Sensitivity analysis on oral PrEP demonstrated that both
TDF/FTC and TDF are efficacious in the prevention of
HIV infection for a variety of high-risk populations irre-
spective of country [32, 33]. Both daily and intermittent
dosing of PrEP have proven effective and safe [15].
Pharmacokinetic modelling of the pre-exposure prophy-
laxis initiative (iPrEx) data revealed that a PrEP dose
regimen of 7 days in the week dosing could achieve as high
as 99% efficacy in the prevention of HIV infection among
MSM. Additionally, an intermittent dosing of 4 days in the
week could result in 96% efficacy [15]. In a laboratory
analysis, detectable blood concentrations of medications
used for PrEP were consistently associated with a protec-
tive effect against HIV acquisition [16].
3.2 Safety Concerns
Adverse reactions to medications used for any inter-
vention are undoubtedly a primary safety concern irre-
spective of the duration of use. A qualitative study of
gay and bisexual sero-discordant male couples assessed
the concerns for adoption of PrEP and revealed that the
main concerns and probable barriers to adoption of PrEP
were short- and long-term side effects or adverse effects
due to intermittent dosing or early termination of drug
use aside from cost and accessibility of the drugs [34].
In this review, we acknowledge that the trials discussed
are short term and do not give the opportunity to assess
the long-term, real-world safety profile of the products
used for PrEP. Pre-exposure prophylaxis is premised on
ARV medications that have been used by people living
with HIV and AIDS for quite some time now, since the
inception of ARVs. We would expect based on current
evidence that the long-term safety profile will be within
acceptable limits with favourable benefit-risk profiles,
considering the impact of PrEP on HIV prevention.
Nonetheless, established adverse drug events such as
renal impairment, reduction in BMD, and gastrointesti-
nal (GI) disturbances captured in scientific literature
concerning the use of TDF should be considered and
monitoring is recommended in PrEP use. An earlier
study by the same authors on the association between the
occurrence of adverse drug events and the modification
of first-line highly active antiretroviral therapy in
Ghanaian patients established that adverse drug events
play a major role in treatment modification and could be
used as a predictor for possible therapy modification
[35].
Other concerns on the use and implementation of PrEP
include resistance to PrEP medications, feasibility,
acceptability and very importantly adherence to PrEP
regimens. Because of the importance of PrEP in reducing
the spread of HIV, it is critical that these concerns are
addressed and fears alleviated to allow for the promising
potential of PrEP. The US Public Health Service recom-
mended guidelines for the use of PrEP in 2014 [21] and the
CDC has interim guidelines for clinicians on the use of
PrEP [36]. Essential factors to be considered before using
PrEP include a confirmed HIV-negative status with a
normal renal function and a negative hepatitis B status
[19, 20]. Recipients of PrEP should be at high risk for HIV
infection, receive behavioural and adherence counselling,
and need to be tested on a minimum of a quarterly basis
during follow-up to ensure they remain HIV negative
[21, 36].
3.3 Adverse Effects
The TDF/FTC (Truvada) combination or TDF alone used
for PrEP generally shows a tolerable profile. In most
studies, the experienced side effects did not differ signifi-
cantly from rates among participants taking placebo. The
side effects or adverse events are basically of GIT origin
and more prevalent at the start of use, but subside within a
month of use. The GIT disturbances are generally upset
abdominal pain, nausea, vomiting or diarrhoea. Other
reported adverses events not of GIT origin are dizziness,
headache, fatigue, weight loss, shortness of breath, cough,
anxiety, fever or joint and muscle pain. In most studies,
these side effects or adverse events did not differ signifi-
cantly from rates among participants taking placebo.
Risk factors in long-term use include age, duration of
treatment with TDF, elevated baseline creatinine levels,
and treatment with a protease inhibitor boosted with
ritonavir combinations and among persons with African
descent as against Caucasians [37]. Side effects considered
potentially serious in the daily use of Truvada or TDF for
PrEP are liver function problems, kidney damage,
hypophosphatamia, proteinaemia or glucosuria, pancreati-
tis, bone thinning and lactic acidosis. Flu-like symptoms,
hypertriglyceridemia, increased creatinine phosphokinase,
unusual dreams and hyperpigmentation are associated with
the use of FTC. The Partners PrEP safety trial [14], the
iPrEx [16] and the Bangkok Tenofovir studies [30] all
recorded increased serum creatinine levels but analyses
indicated that they were statistically insignificant compared
with placebo. However, changes in estimated glomerular
filtration rate were associated with a small but statistically
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significant decline in the estimated glomerular filtration
rate, which was non-progressive and resolved with TDF
discontinuation. The use of TDF alone is also associated
with liver and pancreatic problems as well as depression
[38]. The iPrEx study found a modest effect on BMD
reduction in men who participated in the study. The study
compared changes in BMD between placebo group and
study participants with blood concentrations of tenofovir
diphosphate associated with 90% efficacy and use of two to
three tablets per week. There was a decline of 1% in the hip
and 1.8% in the spine by the end of the study in those with
optimal TDF diphosphate concentrations but this reduced
to normal levels after 1.5 years of stopping PrEP [16]. The
loss of BMD could lead to potential bone fractures and is a
problem for TDF-based PrEP. This could be because of
phosphate wasting. TDF/FTC was well tolerated with some
nausea but little difference was observed between partici-
pants and those taking placebo (9 vs. 5%). No differences
in severe (grade 3) or life-threatening (grade 4) adverse
laboratory events were observed between the active and
placebo groups [8].
In the CAPRISA 004 study [18], hepatic flare (defined
as an event with an abrupt rise of alanine aminotransferase
levels to more than five times the upper limit of normal)
during chronic hepatitis B virus infection and considered to
be the result of a human leukocyte antigen-1 restricted,
cytotoxic T lymphocyte-mediated immune response
against hepatitis B virus [39] was observed for two hep-
atitis B carriers but this did not result in drug discontinu-
ation. In the Partners-PrEP study [14], there were no
significant differences across the study arms with respect to
serious adverse effects including the total of 1% deaths per
arm.
The US MSM safety trial [31] presented no marked
difference in the overall frequency of adverse events
between TDF and placebo groups, but in a subset of men at
a San Francisco site (n = 184), the use of TDF was asso-
ciated with a small but statistically significant decrease in
BMD at the femoral neck (1.1%) and total hip (0.8%
decrease) but no bone fractures were detected. Rates of
nausea and vomiting were higher among the TDF than
among placebo recipients in the first 2 months in the
Bangkok Tenofovir Study [30] but not thereafter. The rates
of adverse drug events, deaths or elevated creatinine were
not different between the TDF and the placebo groups [30].
Concerning the trials with questionable efficacy, the
FEM-PrEP trial [28] presented adverse drug events of
nausea and vomiting, which were transient, and a mild
elevation of liver enzymes was much more common with
the TDF/FTC group than that of placebo group. No change
in renal function was reported in either group. In the
VOICE study [27], a confirmed increase in creatinine
levels was observed in the oral TDF/FTC group than in the
oral placebo group. There were no significant differences
between the active products and placebo groups for other
safety outcomes [27].
3.4 Resistance
Generally, resistance to PrEP is rarely observed in sero-
converters who are infected with HIV after randomisation.
Participants who show resistance are more likely to be the
result of circulating resistance and not necessarily, PrEP
induced. In the PROUD trial, no one acquired resistance to
TDF [29]. Resistant virus reported in studies include one
with TDF-resistant virus (K65R mutation) in a participant
randomised to TDF and one with FTC-resistant virus
(M184V mutation) in a participant randomised to FTC/
TDF from the Partners-PrEP trial [14]. They were found to
be infected at randomisation. A rare TDF resistance
mutation (K65N) was however reported in the TDF arm of
the Partners-PrEP study after randomisation [14]. In the
TDF2 study, K65R, M184V and A62V resistance muta-
tions occurred in one participant in the TDF/FTC group.
The participant was later found to have had HIV infection
at enrolment. The iPrEx study presented two of two men in
the active group and one of eight in the placebo group with
FTC-resistant virus. TDF/FTC resistant virus was detected
in five women (one in the placebo group and four in the
TDF/FTC group) in the FEM-PrEP study [28]. Two women
from the TDF/FTC group who were determined after
enrolment to have had acute HIV infection at baseline had
the virus with the M1841/V mutation associated with FTC
resistance. One other woman also had the M1841/V
mutation but acquired the HIV infection after enrolment.
The development of a resistant mutation seems to be more
common with FTC than TDF. Additional care must be
deployed to ensure that PrEP use is not approved during the
acute infection stage to prevent the development of resis-
tance strains. An abstract authored by Knox et al. presented
at the CROI 2016 conference in Boston, MA, USA titled
‘‘HIV-1 infection with multiclass resistance despite PrEP’’
provided evidence of breakthrough HIV infection irre-
spective of long-term adherence to FTC/TDF (monitored
via clinical and pharmacokinetic data) and described a
resistant strain irrespective of long-term adherence [40]. It
is described as the first such report and more efforts would
be deployed to closely monitor the use of PrEP following
this report.
The other area of concern is sexual and reproductive
health because women of childbearing age are prone to
HIV infection and the use of PrEP in discordant relation-
ships could be useful. The Partners PrEP and the FEM-
PrEP studies showed that TDF based PrEP does not affect
the effectiveness of hormonal contraception and neither
does hormonal contraception affect PrEP efficacy [14, 28].
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There were not significant differences in pregnancy related
and infant adverse reaction including premature births,
congenital anomalies and growth throughout the early
years of life for infants born to women who received PrEP
as against placebo in the Partners PrEP study. Therefore,
PrEP is relatively safe to be used by women of child-
bearing age [14] though, like all medicines, its benefits
should be weighed against any risks that it may pose in
specific individuals.
3.5 Feasibility and Acceptability
Some research on behavioural tendencies has helped to
determine adherence to PrEP, but few studies have asses-
sed the acceptability and use of PrEP. Factors associated
with intentions to use PrEP in a sample of men who have
sex with men (MSM) in USA included the efficacy, costs
and potential side effects of PrEP [41]. Preliminary find-
ings from the PrEP Safety trial showed that MSM attending
the STD clinic in San Francisco had a high interest in
taking PrEP. This trial also demonstrated feasibility of
including PrEP in busy clinical settings, indicating that
PrEP can be accessed at clinics providing HIV care man-
agement [42]. Project PrEP, a study on the acceptability
and feasibility of PrEP among young men who have sex
with men, reported of high feasibility and acceptability of
PrEP [43]. The PROUD study also affirmed the feasibility
of incorporating PrEP in routine activities of clinical set-
tings [29]. Acceptability of PrEP as demonstrated in a
study among MSM and female sex workers in Nairobi and
Mtwapa, Kenya, was also rated as high [44]. Suggestions
proposed in this study included how best to improve the
pill characteristics to make it easy to take, how to reduce
stigma and discrimination from other family members,
certain barriers and facilitators to adhering to PrEP regi-
mens such as lifestyles, dosing regimen and side effects
were identified. Enhanced counselling and commitment to
using the products also improved their ability to adhere to
the regimens despite the challenges.
Participants in all the listed studies were receptive to
monthly HIV testing and counselling, risk reduction
counselling, physical examinations and group-based inter-
vention sessions. Participants were more likely to accept a
daily pill compared with multiple daily pills administra-
tion, especially if they knew their partner was not infected
[43]. The Ipergay trial demonstrated that high-risk MSM
who do not use condoms consistently, accepted on demand
PrEP as a practical alternative to daily PrEP if its effective
[5]. A substudy of The Alternative Dosing to Augment Pre-
Exposure Prophylaxis Pill Taking [45] study involving 37
men in Harlem revealed scepticism and distrust by male
partners and sometimes resulted in unwillingness of part-
ners to engage in sex after learning about their PrEP use,
thus pointing out how stigma and social barriers may
impede adherence and therefore acceptability.
3.6 Adherence
Six clinical trials yielded PrEP efficacy estimates of 0–75%
mostly because of differences in adherence among the
studies [14, 16, 17]. Self-reported adherence to PrEP is
unreliable as the initial clinical trials quickly established
that blood drug concentrations sharply differ from per-
ceived adherence claims. Effective counselling and other
support measures are required in all persons who desire to
use PrEP for HIV prevention.
The iPrEx study [16] clearly illustrated how adherence
produced different outcomes in HIV-negative gay men who
were given a daily pill of TDF and FDC and achieved a
reduction rate of 44% as against men given a placebo. It
was realised that subjects who by self-report and pill count
took the drugs more than 90% of the time reduced the
infection rate by 73% [16]. Meanwhile, another interesting
finding of the trial indicated that while 93% of trial subjects
reported complete compliance, only 51% actually com-
plied effectively when drug concentrations in blood were
determined [16]. The investigators concluded through
calculations that a reduction in the risk of HIV infection
could have been as much as 92% compared with placebo if
the study subjects had complied totally [16]. This confirms
the importance of adherence as a major tool to be deployed
in PrEP. The FEM-PrEP trial [28], which was halted for
futility, reported adherence by self-report and pill count as
high, but plasma drug concentrations showed that only
15–26% of samples from HIV seroconverters had
detectable concentrations of serum TDF and only 26–38%
of non-seroconverting controls. This low level of adher-
ence was recorded as 37% (Table 1) by the researchers and
this may have resulted in the inability to assess the pro-
tective effect of Truvada in FEM-PrEP trial. This again
points to the importance of ensuring adherence in PrEP
management.
Liu et al. [42], examined self-reported medication-tak-
ing experiences, facilitators and barriers of medication
adherence among a geographically diverse online sample
of HIV-uninfected MSM in US. Their multivariable anal-
yses showed that age and sex were likely associated with
adherence. In this study, 1480 men having sex with other
men were surveyed, 806 (54%) of participants indicated
regular taking of medicines, 80% of this number reported
taking medicines for treatment whilst 55% said they take
medicines for preventive purposes. The study also realised
that men aged older than 25 years were more likely to
report excellent adherence together with those who did not
report any adherence barriers. Willingness to use PrEP was
also associated with high likelihood of reporting perfect
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Safety Back pain; ;in bone mass density;
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Adherence 92% (pill count); 77% (MEMS)
ACASI Audio Computer-Assisted Self-Interview Software, ADAPT Alternative Dosing to Augment Pre-Exposure Prophylaxis Pill Taking, ALT
alanine transaminase, CAPRISA Centre for AIDS program of Research in South Africa, FEM PrEP Preexposure Prophylaxis Trial for HIV
Prevention among African Women, FTC emtricitabine, Ipergay Intervention Preventive de l’Exposition aux Risques avec Risques avec et pour
les Gays, iPrEX Iniciativa Profilaxis Pre-Exposicion, MEMS medication event monitoring system, MSM men who have sex with men, NR not
reported, PrEP pre-exposure prophylaxis, PROUD Pre-exposure Prophylaxis to Prevent the Acquisition of HIV-1 Infection, RCT randomised
controlled trial, TDF tenofovir, TGW trans-gender women, VOICE Vaginal and Oral Interventions to Control the Epidemic, : increased, ;
decreased
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30-day adherence. They listed factors that improved med-
ication adherence as establishing a routine, keeping medi-
cation visible and using a pill-box. Forgetfulness, changes
in usual routine, and being busy or away from home were
listed as barriers to adherence [42]. Counselling strategies
to build pill-taking routines can help improve adherence to
PrEP. Daily dosing are much more associated with a high
level of adherence than post-coital use of PrEP, which is
generally low [15].
Following the approval of the use of PrEP in USA and
Europe, reports on adherence have been claimed to be
higher in recent trials and open label extensions as com-
pared with the initial clinical trials. Explanations provided
include available evidence of PrEP efficacy and individual
motivations and reasons for taking PrEP [46].
4 Discussion
The advent of PrEP is a promising turning point in the
prevention of HIV among at-risk groups. TDF-based PrEP
is recommended to prevent HIV infection in tandem with
other preventive measures. From the trials reviewed, it is
evident that PrEP is highly effective against HIV infection
when taken as required. Most importantly, PrEP seems to
be characterised by low adverse effects. Our current review
shows a favourable pattern of adverse events for PrEP
among eligible populations. Side effects can lead to a lack
of compliance, resulting in low levels of adherence (fre-
quency of medicine intake) to pill use. Some reported
symptoms associated with the start of PrEP gradually
resolve. Generally, even for some side effects listed as
serious, such as kidney dysfunction, observed increases in
the serum creatinine level return to normal after the dis-
continuation of PrEP. Tubular renal toxicity from PrEP is
rare and active screening is not recommended. The same
applies to the reduction of BMD after cessation in the use
of TDF and therefore current evidence does not support
constant X-ray monitoring at baseline before initiating
PrEP and while taking TDF/FTC.
Liver toxicity mentioned earlier in the findings was
reported by the D.A.D. study, which looked at the use of
antiretroviral therapy and the risk of end-stage liver disease
and hepatocellular carcinoma in HIV-positive persons. It
concluded among that alongside other antiretroviral agents,
TDF is associated with an increased risk of end-stage liver
disease among HIV-positive patients on long-term therapy.
It also indicated that the unexpected viral hepatitis inde-
pendent TDF association should be investigated further
[47]. The use of TDF-based PrEP is yet to present any case
report involving serious hepatic complications. However,
the regular monitoring of liver enzymes in PrEP uses
would be helpful in preventing possible toxicities.
The correspondent decrease in sexual risk behaviour
among participants in the course of PrEP is very encour-
aging. This is attributed to behavioural intervention
including sexual health counselling and the provision of
condoms across the studies where applicable. Undoubtedly,
behavioural interventions should be an integral part of
PrEP.
Because PrEP is meant for HIV-negative individuals, an
important aspect of PrEP is the identification of people who
are seroconverting [14]. Preliminary testing methods, for
example polymerase chain reaction that can diagnose
people who are recently infected with HIV, are thus
important but expensive. This will enable provision of
treatment options instead of preventive interventions.
Exclusion criteria that run across trials were the low
level of creatinine clearance below 50 mL/min, some cases
of hepatitis and evidence of bone fractures. People who do
not qualify for PrEP but are at risk for HIV should be
encouraged to adhere to good evidence-based sexual
behavioural prevention practices including regular condom
use. The reduction in rates of sex without condoms from 27
to 9% after 24 months of the Partners-PrEP trial [14] is
encouraging and shows that counselling and education on
good sexual practices is complementary on HIV preven-
tion. Several other studies [48–51], including studies con-
ducted in West African women with TDF, also demonstrate
a reduction in high-risk sexual behaviour with counselling
during PrEP [52]. TDF/FTC is the only medication with a
label indication as PrEP against HIV infection, but new
PrEP drugs and formulations are being considered for
future trials (Maraviroc, intravaginal rings containing
dapivirine and TDF) and long-acting injecta-
bles (rilpivirine, carbotegravir). These newer agents also
present a good safety profile when used for the treatment of
HIV infection, but use for PrEP purposes in HIV-unin-
fected persons is unknown as efficacy and clinical safety is
yet to be established [37]. A new formulation, tenofovir
alafenamide that provides 90% lower plasma levels of TDF
concentrations compared with standard TDF, has recently
being approved by the FDA. It is claimed to have favour-
able renal and bone safety profile better than original TDF,
unfortunately as at the time of this review efficacy and
safety in PrEP has not been established in HIV-negative
populations [37].
5 Conclusion
The medications currently studied for PrEP (TDF and FTC)
are efficacious and seem to have a good safety profile
within the average short period of 3 years studied.
Emphasis on the use of additional prevention methods
should be made alongside. The main adverse effects
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observed with PrEP are GI related and graded below 2 for
severity. These are basically mild to moderate nausea,
vomiting and diarrhea. Major concerns are renal, hepatic
and bone toxicity, but these are transient and non-pro-
gressive and quickly resolved after discontinuation of TDF.
Overall, the benefit-risk profiles of the products used for
PrEP appear favourable.
PrEP as an intervention to reduce HIV transmission
appears to have a safe benefit-risk profile in clinical trials.
It is recommended for widespread use but adherence
monitoring and real-world safety surveillance are critical in
the post-marketing phase to ensure that the benefits
observed in clinical trials are maintained in real-world use.
Behavioural counselling and assurance of safety and effi-
cacy are important components of PrEP. Other factors of
PrEP implementation that have been suggested include
improving access, averting stigma, cost effectiveness, and
education on PrEP to improve knowledge and assure
people of the efficacy profile of products used for PrEP.
Further studies must ultimately look at how safe and ben-
eficial PrEP could be for pregnant women and women
seeking to get pregnant.
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